🔎 Trials Near Me

Domov › Sklerodermia › Texas

Klinické štúdie Sklerodermia v štáte Texas

12 štúdií pre Sklerodermia hľadá účastníkov v zariadeniach v štáte Texas.

Mestá v štáte Texas

Oficiálny text štúdie (anglicky)

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  • Tekton Research, Inc - West Gate Boulevard, Austin
  • Arthritis & Rheumatology Institute - Frisco, Frisco
  • The University of Texas Health Science Center at Houston, Houston
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07497087

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • a 2 ďalších
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT03816345

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

  • GSK Investigational Site, Denison
  • GSK Investigational Site, El Paso
Prebieha náborFáza 2/3
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 9. 2026 · NCT05878717

Platform Clinical Study for Conquering Scleroderma

  • University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 18. 8. 2026 · NCT06195072

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

  • Nkarta Investigational Site, Dallas
  • Nkarta Investigational Site, Houston
Prebieha náborFáza 1/2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 7. 8. 2026 · NCT06733935

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

  • Artiva Investigational Site Arlington, Arlington
  • Artiva Investigational Site Bellaire, Bellaire
  • Artiva Investigational Site Irving, Irving
  • a 4 ďalších
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 31. 7. 2026 · NCT06991114

A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis

  • The University of Texas Health Science Center at Houston, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 8. 7. 2026 · NCT06827977

Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository

  • UT Southwestern Medical Center - Department of Dermatology, Dallas
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
Do veku 90 · Všetky pohlavia · Aktualizované 12. 5. 2026 · NCT01808937

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

  • MD Anderson Cancer Center, Houston
  • The University of Texas Health Science Center at Houston, Houston
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 15. 4. 2026 · NCT06434363

A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

  • Galderma Investigational Site#7096, Arlington
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 31. 3. 2026 · NCT07047690

Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis

  • The University of Texas Health Science Center at Houston, Houston
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 26. 6. 2025 · NCT05989763

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

  • aTyr Investigative Site, Dallas
  • aTyr Investigative Site, Houston
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 7. 5. 2025 · NCT05892614

Z ClinicalTrials.gov, dáta načítané 4. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.